Nanomedicine (London, England)最新文献_第2页

Immunomodulatory nanoplatforms with multiple mechanisms of action in cancer treatment. 在癌症治疗中具有多种作用机制的免疫调节纳米平台。

Nanomedicine (London, England) Pub Date : 2025-06-01 Epub Date: 2025-05-07 DOI: 10.1080/17435889.2025.2500906

Rodolfo Villa, Ya-Ping Shiau, Sohaib Mahri, Kelsey Jane Racacho, Menghuan Tang, Qiufang Zong, Donovan Ruiz, Judy Kim, Yuanpei Li

{"title":"Immunomodulatory nanoplatforms with multiple mechanisms of action in cancer treatment.","authors":"Rodolfo Villa, Ya-Ping Shiau, Sohaib Mahri, Kelsey Jane Racacho, Menghuan Tang, Qiufang Zong, Donovan Ruiz, Judy Kim, Yuanpei Li","doi":"10.1080/17435889.2025.2500906","DOIUrl":"10.1080/17435889.2025.2500906","url":null,"abstract":"Cancer immunotherapies have transformed oncology by utilizing the immune system to target malignancies; however, limitations in efficacy and potential side effects remain significant challenges. Nanoparticles have shown promise in enhancing drug delivery and improving immune activation, with the potential for numerous modifications to tailor them for specific environments or targets. Integrating nanoplatforms offers a promising avenue to overcome these hurdles, enhancing treatment outcomes and reducing adverse effects. By improving drug delivery, targeting, and immune modulation, nanoplatforms can unlock the full potential of cancer immunotherapy. This review explores the role of nanoplatforms in addressing these limitations and enhancing cancer immunotherapy outcomes, examining various types of nanoplatforms. Understanding the mechanisms of immunomodulation through nanoplatform deliveries is crucial. We discuss how these nanoplatforms interact with the tumor microenvironment, modulate tumor-associated macrophages and regulatory T cells, activate immune cells directly, enhance antigen presentation, and promote immunological memory. Further benefits include combination approaches integrating nanoplatforms with chemotherapy, radiotherapy, and phototherapy. Immunotherapy is a relatively new approach, but numerous clinical studies already utilize nanoplatform-based immunotherapies with promising results. This review aims to provide insights into the potential of nanoplatforms to enhance cancer immunotherapy and pave the way for more effective and personalized treatment strategies.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1321-1338"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anticancer efficacy of dual-loaded SLNs with Doxorubicin (DOX) and Pterostilbene (PTS): formulation, characterization, and evaluation for breast cancer. 多柔比星（DOX）和紫檀芪（PTS）双负载sln的抗癌效果：乳腺癌的配方、表征和评价

Nanomedicine (London, England) Pub Date : 2025-06-01 Epub Date: 2025-05-06 DOI: 10.1080/17435889.2025.2501526

Harneet Marwah, Janmejay Pant, Kamal Shah, Perwez Alam, Hitesh Kumar Dewangan

{"title":"Anticancer efficacy of dual-loaded SLNs with Doxorubicin (DOX) and Pterostilbene (PTS): formulation, characterization, and evaluation for breast cancer.","authors":"Harneet Marwah, Janmejay Pant, Kamal Shah, Perwez Alam, Hitesh Kumar Dewangan","doi":"10.1080/17435889.2025.2501526","DOIUrl":"10.1080/17435889.2025.2501526","url":null,"abstract":"Aims: This study aimed to develop optimized doxorubicin (DOX) and pterostilbene (PTS) co-loaded solid lipid nanoparticles (SLNs) for synergistic triple-negative breast cancer (TNBC) therapy, enhancing drug stability, tumor targeting, and therapeutic efficacy.Materials & methods: Calibration curves for DOX and PTS were validated. Synergy was assessed in MDA-MB-231 cells via Combination Index (CI) and Loewe-HSA models. SLNs were optimized using Box-Behnken Design (BBD), evaluating lipid content, surfactant concentration, and sonication time. Formulations were characterized by Zetasizer, high-resolution transmission electron microscopy (HR-TEM), Fourier-transform infrared (FTIR), X-ray powder diffraction (XRD), and differential scanning calorimetry (DSC). In in-vitro cytotoxicity, Reactive Oxygen Species (ROS) generation, apoptosis, and mitochondrial depolarization were assessed. Pharmacokinetics and tumor regression were studied in rats.Results: The optimal 1:4 (DOX:PTS) ratio showed strong synergy (CI = 0.83). BBD-optimized SLNs had 97.92 nm size, high entrapment (DOX: 54.%; PTS: 77.5%), and pH-responsive release (78.78% DOX at pH 5.5). SLNs exhibited enhanced cytotoxicity (IC₅₀ = 0.833 µg/mL), elevated ROS (59.5%), and apoptosis induction. In in-vivo, SLNs prolonged circulation, increased tumor accumulation, and reduced tumor volume (701.50 ± 11.83 mm3 vs. 3506.58 ± 17.06 mm3 control).Conclusions: DOX-PTS SLNs demonstrated synergistic anticancer effects, improved stability, and targeted delivery, offering a promising strategy for TNBC treatment.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1249-1265"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From conventional therapy to novel nano-based approaches. A focus on prostate cancer. 从传统疗法到新型纳米疗法。对前列腺癌的关注。

Nanomedicine (London, England) Pub Date : 2025-06-01 Epub Date: 2025-05-07 DOI: 10.1080/17435889.2025.2501513

Lorenzo Chiaverini, Giarita Ferraro, Riccardo Di Leo, Elisabetta Barresi, Diego La Mendola, Francesco Bartoli, Luca Famlonga, Cristina Satriano, Pinuccia Faviana, Alessandro Zucchi, Matteo Pacini, Jürgen Gailer, Chiara Giacomelli, Tiziano Marzo

引用次数: 0

Recent advances in the application of polymeric nanoparticles to the pulmonary delivery of mRNA. 聚合纳米颗粒在mRNA肺传递中的应用进展。

Nanomedicine (London, England) Pub Date : 2025-05-30 DOI: 10.1080/17435889.2025.2509477

Peyton M Panovich, Aditi Ganesan, Amogh R Angadi, Alexandra S Piotrowski-Daspit

{"title":"Recent advances in the application of polymeric nanoparticles to the pulmonary delivery of mRNA.","authors":"Peyton M Panovich, Aditi Ganesan, Amogh R Angadi, Alexandra S Piotrowski-Daspit","doi":"10.1080/17435889.2025.2509477","DOIUrl":"https://doi.org/10.1080/17435889.2025.2509477","url":null,"abstract":"Messenger RNA (mRNA)-based therapeutics offer the potential to treat a variety of pulmonary disorders that arise due to genetics, infectious diseases, and chronic respiratory conditions. However, various physiological barriers in the lungs, such as mucociliary clearance, macrophage phagocytosis, and lung surfactant interference, present challenges for efficient mRNA delivery. Polymeric nanoparticles (NPs) have emerged as a therapeutic platform for delivering mRNA therapeutics due to their stability, tunability, and controlled release properties, making them suitable and potentially ideal for encapsulating and protecting mRNA molecules for delivery in vivo. Continued advances in polymer and NP design have improved mucus penetration and cellular uptake upon lung delivery; further, administration via local and systemic routes enable modulation of NP biodistribution. These advancements benefit the potential treatment of a range of pulmonary diseases, including viral infections, cystic fibrosis (CF), asthma, and lung cancer, by facilitating immune modulation and genetic therapy delivery. In this review, we explore how polymeric NPs address disease-specific requirements and physiological challenges to expand the potential for therapeutic mRNAs in the lung.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-17"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

Nanomedicine (London, England) Pub Date : 2025-05-30 DOI: 10.1080/17435889.2025.2514293

引用次数: 0

Emerging nanomaterials capable of effectively facilitating osteoblast maturation. 能够有效促进成骨细胞成熟的新兴纳米材料。

Nanomedicine (London, England) Pub Date : 2025-05-27 DOI: 10.1080/17435889.2025.2511465

Hoda Elkhenany

{"title":"Emerging nanomaterials capable of effectively facilitating osteoblast maturation.","authors":"Hoda Elkhenany","doi":"10.1080/17435889.2025.2511465","DOIUrl":"https://doi.org/10.1080/17435889.2025.2511465","url":null,"abstract":"Efficient osteoblast maturation is essential for successful bone regeneration, yet achieving this goal remains challenging. This review explores the emerging role of nanomaterials in promoting osteoblast differentiation and bone formation. A literature search was conducted in the Web of Science Core Collection in February 2025, covering publications from 2014 to 2024 and limited to articles and proceedings. Keywords included \"nanoparticles\" and \"osteoblast.\" Among the most extensively studied nanomaterials were hydroxyapatite, carbon-based, and bioactive glass nanoparticles (NPs). These materials influence osteoblast function through intracellular mechanisms, including enhanced mitochondrial activity, autophagy, and osteoinductive gene expression. Additionally, they modulate the extracellular microenvironment by mimicking the native bone matrix, releasing bioactive ions, and reducing inflammation and oxidative stress. Notably, several NP-based systems have reached clinical application, including Signafuse (a bioactive calcium phosphate composite), nanoLOCK (a nanostructured titanium spinal implant), and Vitoss (a synthetic bone graft of nanocrystalline calcium phosphate). More recently, multimodal NPs that integrate different NP types and combine surface roughness, ion release, and chemical cues offer synergistic effects. These materials provide a dual-function approach, targeting both intracellular processes and the bone microenvironment. Their ability to modulate inflammation, oxidative stress, and cellular signaling underscores their translational potential in regenerative medicine and bone tissue engineering.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-17"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Repairing and preserving the cellular powerplant with nanotechnology. 用纳米技术修复和保存细胞动力装置。

Nanomedicine (London, England) Pub Date : 2025-05-26 DOI: 10.1080/17435889.2025.2510188

John Soukar, Kanwar Abhay Singh, Akhilesh K Gaharwar

引用次数: 0

Nanovesicular ultra-deformable transferosomes and transgelosomes for ocular drug delivery. 用于眼部药物传递的纳米泡状超变形转移体和转胶体。

Nanomedicine (London, England) Pub Date : 2025-05-26 DOI: 10.1080/17435889.2025.2510197

Debadatta Mohapatra, Timothy W Corson

引用次数: 0

Synthesis and biocompatibility studies of 2D molybdenum carbide (MXene) nanosheets and their potential uses. 二维碳化钼（MXene）纳米片的合成、生物相容性研究及其应用前景。

Nanomedicine (London, England) Pub Date : 2025-05-26 DOI: 10.1080/17435889.2025.2509473

Sesuraj Balasamy, Preethi Sakthivelan, Vasanth Magesh, Ashok K Sundramoorthy

{"title":"Synthesis and biocompatibility studies of 2D molybdenum carbide (MXene) nanosheets and their potential uses.","authors":"Sesuraj Balasamy, Preethi Sakthivelan, Vasanth Magesh, Ashok K Sundramoorthy","doi":"10.1080/17435889.2025.2509473","DOIUrl":"https://doi.org/10.1080/17435889.2025.2509473","url":null,"abstract":"Aims: This study aims to evaluate the biocompatibility and explore the potential biomedical applications of two-dimensional (2D) molybdenum carbide (Mo₂CTх) MXene.Methods: Mo₂CTх MXene was synthesized by etching Mo₂Ga₂C using a Minimally Intensive Layer Delamination (MILD) method combined with hydrofluoric acid (HF). The structural and functional characteristics of the resulting material were characterized using UV-Vis, FT-IR, XRD, and FESEM. Antimicrobial activity was assessed against Staphylococcus aureus and Shigella sonnei, while biocompatibility was evaluated through in vitro testing on A549 lung epithelial cells and in vivo analysis using zebrafish embryos.Results: UV-Vis analysis showed characteristic absorption peaks at 220 nm and 550 nm. FT-IR confirmed the presence of surface functional groups. XRD results indicated high phase purity, and FESEM revealed a typical layered 2D morphology. Antimicrobial testing demonstrated a concentration-dependent response, with stronger inhibitory effects against S. aureus than S. sonnei. Biocompatibility studies showed high cell viability at low concentrations and no significant toxicity or morphological abnormalities in zebrafish embryos.Conclusion: Mo₂CTх MXene exhibits strong antimicrobial activity alongside excellent biocompatibility, highlighting its promise for biomedical applications. However, further studies focusing on long-term safety and functional surface modifications are needed to support its use in targeted therapeutic interventions.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and in vivo biodistribution of folate-targeted nanolipid system for erlotinib in breast cancer treatment. 厄洛替尼治疗乳腺癌的叶酸靶向纳米脂系统的开发和体内生物分布。

Nanomedicine (London, England) Pub Date : 2025-05-26 DOI: 10.1080/17435889.2025.2508135

Bharti Mangla, Tabish Pathan, Pankaj Kumar, Geeta Aggarwal

{"title":"Development and in vivo biodistribution of folate-targeted nanolipid system for erlotinib in breast cancer treatment.","authors":"Bharti Mangla, Tabish Pathan, Pankaj Kumar, Geeta Aggarwal","doi":"10.1080/17435889.2025.2508135","DOIUrl":"https://doi.org/10.1080/17435889.2025.2508135","url":null,"abstract":"Aim: The aim of the study was to develop folate targeted nanolipid carrier system (FA-ERT-NLCs) and study its in vivo oral biodistribution study for its absorption mechanism.Materials & methods: Folic acid was conjugated through pyridine and EDC chemistry. FA-ERT-NLCs was developed by high-pressure homogenization and parameters were optimized through design expert software. FA-ERT-NLCs were evaluated through in vitro characterization, Ex vivo and in vivo biodistribution studies. Moreover, female Wistar rats were used in this study.Results: Findings showed that targeted NLCs were found in nanometric range (182.34 nm) with negatively charge surface and PDI was found to be -16.2 mV and 0.203. The folate content in the conjugate was measured and found to be 71.33%. The depth of ERT and FC-ERT-NLCs was found to be 20 µm and 80.2 µm in rat intestine. Developed formulation was effective against MCF-7 cell lines. The IC50 values were found to be 526.2 µg/mL for ERT and 333.7 µg/mL for FC-ERT-NLCs. FA-ERT-NLCs are absorbed through intestine by lymphatic system.Conclusion: This study showed a promising targeted strategy for effective and safer breast cancer treatment.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0